Kernal Bio Awarded up to $48 Million from ARPA-H to Develop Lower Cost in vivo CAR T-cell Therapies for Hematological Cancers and Autoimmune Disease

Funds will advance in vivo CAR T-cell program and aims to improve cancer care by providing CAR T-cell therapies at a lower cost to patients ...